Actively Recruiting
Investigating Biomarkers in Tumor and Blood to Evaluate Cancer Immunotherapy Response in Lung and Esophageal Cancer Patients
Led by Zhao Jun · Updated on 2025-01-24
50
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how immunotherapy affects the immune environment within tumors and in the blood of patients with lung and esophageal cancer. They aim to identify biological markers that can predict how well patients respond to cancer immunotherapy by studying specific T-cell populations involved in killing cancer cells. The study involves analyzing tumor tissues and blood samples taken before and after immunotherapy treatment. The study collects tumor tissue samples obtained from surgery and peripheral blood mononuclear cells from patients receiving PD-1/PD-L1 antibody immunotherapy. These samples undergo advanced testing methods such as single-cell RNA sequencing, Multiplex immunohistochemistry, flow cytometry, and ELISPOT. In vitro, peripheral blood mononuclear cells are co-incubated with nanoparticles carrying tumor antigens to detect T cells related to the effectiveness of immunotherapy. Participants will have tumor tissue and blood samples collected before and after immunotherapy to analyze changes in specific T-cell subpopulations. Researchers will monitor immune cell subsets in the tumor microenvironment and peripheral blood within one month after completing immunotherapy. The study measures immune responses and seeks biomarkers linked to treatment outcomes, with ongoing follow-up to assess patient prognosis.
CONDITIONS
Official Title
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a pathological diagnosis of lung cancer or esophageal cancer who have agreed to receive PD-1/PD-L1 antibody immunotherapy
- Age between 18 and 80 years old
- ECOG PS score of 0 or 1
- Adequate organ and bone marrow function
- Anticipated survival time of at least 12 weeks
- Willing and able to provide written informed consent
You will not qualify if you...
- Patients with hematogenic infectious diseases, such as HIV, hepatitis B or hepatitis C
- Patients with tumor emergencies that require immediate treatment
- Poor vascular conditions
- Abnormal coagulation function or receiving anticoagulant or thrombolytic therapy
- Patients with psychiatric disorders or severe mental illnesses
- Patients who have difficulty communicating or are unable to be followed up for a long time
- Other situations that are not suitable for inclusion in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The first affiliated hospital of soochow university
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
M
Mi Liu
J
Jun Zhao
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here